Houston Rx Sermorelin and Tirzepatide/Niacinamide Injections
Sermorelin sterile injectable solution lacks process control, and Tirzepatide/Niacinamide injection lacks assurance of sterility.
Moderate risk
Taking it may cause temporary or medically reversible health problems. Serious harm is unlikely.
FDA Class II recall · How risk is rated
What happened
Houston Rx LLC recalled Sermorelin sterile injectable solution and Tirzepatide/Niacinamide injection. The Sermorelin lacks process control, and the Tirzepatide/Niacinamide lacks assurance of sterility. The recall began September 25, 2026, and was added to the FDA's Enforcement Report on October 13, 2026.
Summary by Recall Canary from the FDA notice.
What to do
We don't have product-specific instructions for this recall. FDA's general advice for medicine recalls:
- Check the FDA or company notice for instructions specific to this product.
- Ask your pharmacist or doctor whether your lot is affected and what to do.
Is yours affected?
2 products
Affected if its lot code is listed.
Tirzepatide/Niacinamide 2mL vial (
Reason: Lack of assurance of sterility.
- Strength
- 40 mg
- Lot
- TZN-080326-20
- 2-2
Sermorelin
Reason: Lack of process control
- Strength
- 1 mg/mL
- Lot
- SER-081726-1-10
Details
- Company began the recall
- Event ID
- 99990
- Company
- Houston Rx LLC
- Hazard
- Sterility failure
Company began the recall
Added to FDA's Enforcement Report · Classified by FDA
Listed on Recall Canary
